Artivion Inc (AORT)vsBoston Scientific Corp (BSX)
AORT
Artivion Inc
$19.40
-3.48%
HEALTHCARE · Cap: $998.73M
BSX
Boston Scientific Corp
$44.23
-2.06%
HEALTHCARE · Cap: $60.84B
Smart Verdict
WallStSmart Research — data-driven comparison
Boston Scientific Corp generates 4272% more annual revenue ($21.07B vs $481.88M). BSX leads profitability with a 16.6% profit margin vs -3.6%. BSX appears more attractively valued with a PEG of 0.63. BSX earns a higher WallStSmart Score of 62/100 (C+).
AORT
Hold35
out of 100
Grade: F
BSX
Buy62
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-28.3%
Fair Value
$31.25
Current Price
$19.40
$11.85 premium
Margin of Safety
-9.2%
Fair Value
$39.15
Current Price
$44.23
$5.08 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Large-cap with strong market position
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 20.2%
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of 4.9%
Expensive relative to growth rate
1.4% revenue growth
Distress zone — elevated risk
Earnings declined 21.5%
Comparative Analysis Report
WallStSmart ResearchBull Case : AORT
The strongest argument for AORT centers on Price/Book.
Bull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, P/E Ratio. Profitability is solid with margins at 16.6% and operating margin at 20.2%. PEG of 0.63 suggests the stock is reasonably priced for its growth.
Bear Case : AORT
The primary concerns for AORT are EPS Growth, Market Cap, Operating Margin.
Bear Case : BSX
The primary concerns for BSX are Revenue Growth, Altman Z-Score, EPS Growth.
Key Dynamics to Monitor
AORT profiles as a turnaround stock while BSX is a value play — different risk/reward profiles.
AORT carries more volatility with a beta of 1.28 — expect wider price swings.
AORT is growing revenue faster at 9.2% — sustainability is the question.
BSX generates stronger free cash flow (868M), providing more financial flexibility.
Bottom Line
BSX scores higher overall (62/100 vs 35/100), backed by strong 16.6% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Artivion Inc
HEALTHCARE · MEDICAL DEVICES · USA
Artivion Inc. manufactures, processes and distributes implantable human tissues and medical devices worldwide.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?